1. Association between Molecular Genetic Markers of DNA Repair and Cell Cycle Control Genes and Response to Platinum-Based Chemotherapy in Ovarian Cancer Patients
- Author
-
T M Zavarikina, M B Stenina, P K Brenner, G N Khabas, D S Khodirev, Yu V Nosova, A S Tyulyandina, S V Khokhlova, M A Kapralova, and A V Asaturova
- Subjects
Mutation ,business.industry ,DNA repair ,Promoter ,General Medicine ,medicine.disease_cause ,medicine.disease ,General Biochemistry, Genetics and Molecular Biology ,XRCC1 ,Genotype ,Cancer research ,Medicine ,Allele ,business ,Ovarian cancer ,Gene - Abstract
We analyzed associations of polymorphic markers of DNA repair genes (XRCC1, ERCC2), cell cycle control genes (TP53, MDM2, and CDKN1A), methylation of promoter region, and mutation 5382insC of BRCA1 gene in ovarian cancer with effectiveness of platinumbased chemotherapy assessed by the median of progression-free survival time for markers of DNA repair genes and by relapse risk for all studied markers. An increase in the median of progression-free survival time for carriers of the Gln allele (р=0.025) and Gln/Gln genotype (р=0.022) of the Gln399Arg XRCC1 was observed during the 19-months period after chemotherapy. In carriers of C/C genotype of 5382insC mutation of BRCA1 gene (n=6), no relapses were observed (р=0.035), while 17 of 49 patients without this mutation developed relapses. Of 14 patients with BRCA1 gene function inactivation due to promoter methylation or the presence of the C/C genotype of 5382insC, one relapse was observed (p=0.033). Multivariate analysis revealed an association of markers of the XRCC1, TP53, MDM2 genes, BRCA1 gene inactivation, and type of surgery with the risk of relapse during the follow-up period up to 19 months after the end of chemotherapy (р≤0.0007).
- Published
- 2021